Estimated Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in 2019.

Journal Article (Journal Article)

IMPORTANCE: Low-dose aspirin (LDA) is one of the few evidence-based interventions for preventing preeclampsia, which is a leading cause of maternal or fetal morbidity and mortality. Current guidelines recommend LDA based on the presence of risk factors for preeclampsia, but the population-based prevalence of these factors is unknown. OBJECTIVE: To estimate population-level prevalence of preeclampsia risk factors used in prophylactic LDA guidelines for pregnant patients and the association of these risk factors with reported rates of pregnancy-related hypertension. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted using National Center for Health Statistics birth certificate data to describe the frequency of pregnant individuals with moderate to high-risk factors for preeclampsia and pregnancy-related hypertension rates. The study used all birth records in the United States for the 2019 calendar year. EXPOSURES: Documentation of preeclampsia risk factors: multifetal gestation, pregestational diabetes, chronic hypertension (high-risk factors) and nulliparity, a body mass index greater than 30, African American race, a maternal age 35 years or older, an interval of more than 10-years since last birth, and having low socioeconomic status (moderate risk factors). MAIN OUTCOMES AND MEASURES: Prevalence of each risk factor alone and in combinations leading to a recommendation for LDA; incidence of pregnancy-related hypertension by risk factor and combinations of risk factors. RESULTS: There were 3 695 019 pregnancies in 2019, including 528 778 with no risk factors, 169 540 with 1 or more high-risk factors, and 2 996 701 with 1 or more moderate-risk factors. The mean (SD) of the cohort was 29.1 (5.8) years. Multifetal gestation was the most common high-risk factor and found in 123 995 pregnancies (3.4%), and low socioeconomic status was the most common moderate-risk factor and present in 1 732 729 pregnancies (46.9%). Based on 2021 criteria (a single high- or moderate-risk factors for preeclampsia), 3 166 241 pregnant patients (85.7%) were eligible for LDA. The incidence of pregnancy-related hypertension increased with the number of moderate-risk factors. The 2021 guidelines suggest considering or recommend LDA in 92.3% of pregnancies diagnosed with pregnancy-related hypertension. CONCLUSIONS AND RELEVANCE: These data support the recently published guidelines and suggest further simplified guidelines recommending LDA to patients with any single moderate-risk factors.

Full Text

Duke Authors

Cited Authors

  • Wheeler, SM; Myers, SO; Swamy, GK; Myers, ER

Published Date

  • January 4, 2022

Published In

Volume / Issue

  • 5 / 1

Start / End Page

  • e2142343 -

PubMed ID

  • 34982156

Pubmed Central ID

  • PMC8728614

Electronic International Standard Serial Number (EISSN)

  • 2574-3805

Digital Object Identifier (DOI)

  • 10.1001/jamanetworkopen.2021.42343


  • eng

Conference Location

  • United States